Clinical trials: Human Immunodeficiency Virus I Infection
- Condition Human Immunodeficiency Virus I Infection
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Infection, Human Immunodeficiency Virus
Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations
Dolutegravir (DTG) and lamivudine (3TC) are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
- Trial name
- NCT02738931
- Testing
- Dolutegravir 50 mg tablet, Lamivudine 300 mg tablet, Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus
Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects
This study will be a phase 1, open label, parallel group, three period crossover study to evaluate the effect of dolutegravir (DTG) on the steady state pharmacokinetics of metformin and on the safety and tolerability of…
- Trial name
- NCT02064374
- Testing
- Metformin 500 mg q12h, Dolutegravir 50 mg q24h, Dolutegravir 50 mg q12h
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus I Infection, Human Immunodeficiency Virus II Infection
A Study to Evaluate the Performance, Usability, and Result Interpretation of INSTI® HIV Self-Test
The objective of this study is to evaluate the performance, usability, and result interpretation of the INSTI® HIV Self-Test (referred to INSTI® HIV ST) in the intended use population across the United States (US).
- Trial name
- NCT06368453
- Testing
- INSTI® HIV Self-Test
- Where
- United States
- Volunteers
- 1,728 people, healthy volunteers welcome
- Sponsor
- bioLytical Laboratories
Infection, Human Immunodeficiency Virus
Dolutegravir Renal Impairment Study
Dolutegravir (DTG, GSK1349572) is an integrase inhibitor being developed for the treatment of human immunodeficiency virus (HIV)-1 infection by GlaxoSmithKline (GSK) on behalf of Shionogi-ViiV Healthcare LLC.
- Trial name
- NCT01353716
- Testing
- Dolutegravir 50 mg
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus
Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet
This is an open-label, randomized, crossover study in healthy adult subjects with 5 treatment groups over 5 dosing periods. This study will evaluate pharmacokinetic parameters and relative bioavailability of a dispersible…
- Trial name
- NCT02893488
- Testing
- DTG/ABC/3TC FDC DISPERSIBLE TABLET, EPZICOM (ABC/3TC), TIVICAY (DTG)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Healthy Subjects, Infection, Human Immunodeficiency Virus
DDI Study of Etravirine and GSK1265744
The primary objective of this study is to compare steady-state plasma PK, safety and tolerability of GSK1265744 with and without etravirine
- Trial name
- NCT00920296
- Testing
- GSK1265744
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infection, Human Immunodeficiency Virus
A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult Subjects
Human immune virus (HIV) infected subjects may take mineral supplements in combination with their antiretroviral medications. Calcium and Iron supplementations are commonly used and both of these have the potential to interact…
- Trial name
- NCT01762995
- Testing
- Dolutegravir 50 mg, Calcium Carbonate 1200 mg, Ferrous Fumarate 324 mg
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Healthy
A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults
The purpose of this study is to assess the safety and tolerability of Modified Vaccinia Ankara (MVA) Mosaic vaccine in healthy adult participants.
- Trial name
- MENSCH (NCT02218125)
- Testing
- MVA Mosaic
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Healthy Subjects, Infection, Human Immunodeficiency Virus
GSK1349572 Drug Interaction Study With Protease Inhibitors
A study in healthy volunteers to determine whether there is a drug interaction between GSK1349572 and the HIV protease inhibitors lopinavir/ritonavir and darunavir/ritonavir
- Trial name
- NCT00774735
- Testing
- GSK1349572
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C, HCV
VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer
The purpose of this study is to determine the effect of EFV (Efavirenz) and TDF (Tenofovir disoproxil fumarate) on the pharmacokinetics of TVR (Telaprevir) and to determine the effect of TVR on the pharmacokinetics of EFV and…
- Conditions
- Hepatitis C, HCV, HIV, AIDS
- Trial name
- NCT00828789
- Testing
- Efavirenz; Tenofovir disoproxil fumarate; Telaprevir
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tibotec BVBA
HIV-1
PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir
The purpose of the study is to determine the safety, tolerability and plasma pharmacokinetics (pk) (i.e., the levels of TMC558445 circulating in your blood over time) of increasing single oral doses of TMC558445 and of multiple…
- Trial name
- NCT00838760
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Healthy Subjects, Infection, Human Immunodeficiency Virus
Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs
The purpose of this study is to evaluate the effect of GSK2448761 on CYP450 metabolic probes and to evaluate the 2-way interaction between GSK2448761 and two ritonavir-boosted protease inhibitors that are commonly used in…
- Trial name
- NCT00920088
- Testing
- darunavir/ritonavir, lopinavir/ritonavir, Midazolam
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infection
Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together
The aim of the study is to see if apricitabine or tipranavir affect the levels of each other in the blood (pharmacokinetic interaction) when they are dosed together.
- Trial name
- NCT00352066
- Testing
- apricitabine
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Avexa
Human Immunodeficiency Virus I Infection, Human Immunodeficiency Virus II Infection
A Study to Evaluate the Performance of INSTI® HIV Self Test When Performed by Unobserved Intended Users in the US
The objective of this study is to evaluate the performance of INSTI® HIV Self Test with unobserved intended user population. The purpose of this study is to document if a lay person, unassisted by a healthcare worker, is able to…
- Trial name
- NCT07061912
- Testing
- NSTI® HIV Self-Test
- Where
- Canada
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- bioLytical Laboratories
Infection, Human Immunodeficiency Virus
Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects
Treatment of human immunodeficiency virus (HIV) infection requires daily oral administration of a combination of antiretroviral drugs to reduce the patient's HIV levels.
- Trial name
- NCT02373930
- Testing
- DTG 50 mg, RPV 25 mg, DTG/RPV 50 mg/25 mg: Product Code AS
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus
A Study to Evaluate the Effect of High Fat Meal on Cabotegravir
Cabotegravir is being developed for the treatment of human immunodeficiency virus (HIV) 1 infection. Specifically, it is being developed as a component of a 2-drug maintenance regimen (post-induction of viral suppression) that…
- Trial name
- NCT02799264
- Testing
- Cabotegravir 30 mg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus I
A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.
This is a single-center, open-label, three-period, fixed-sequence cross over study in healthy adult subjects. A total of approximately 16 healthy subjects will be enrolled to provide data from 12 evaluable subjects.
- Trial name
- NCT01283100
- Testing
- GSK1349572, GSK2248761
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus
Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects
CAB is an integrase inhibitor that is currently in Phase 2 clinical trials for the treatment and prevention of human immunodeficiency virus-1 (HIV-1) infection.
- Trial name
- NCT02411435
- Testing
- CAB, RIF
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus I
A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™
This is a study in healthy adult subjects to evaluate the bioequivalence of a Combined Formulated Tablet compared with maraviroc and Combivir administered concurrently versus maraviroc + Combivir.
- Trial name
- NCT01597648
- Testing
- Maraviroc, Combivir, GSK2838510
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study to Investigate the Effect of Steady-State TMC278 on the Pharmacokinetics of a Single Dose of Digoxin
The purpose of this study is to investigate the effect of steady-state (constant concentration of medication in the blood) TMC278 on the single dose pharmacokinetics (what the body does to the medication) of digoxin.
- Trial name
- NCT01519128
- Testing
- Treatment A: Digoxin, Treatment B: TMC278
- Where
- Belgium
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Janssen R&D Ireland